ICAM-3 is the major ligand for LFA-1 (CD11a/CD18) in the resting state.
| Inventor | Institute |
|---|---|
| Joyce Taylor-Papadimitriou | University of Oxford |
| Cat. #: | 151110 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology;Cell signaling and signal transduction;Immunology |
| Application: | ELISA ; FACS ; IHC ; IF ; IP ; RIA ; WB |
| Target: | ICAM3 (CD50) |
| Reactivity: | Human |
| Clone: | ICAM 3.1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Intercellular Adhesion Molecule 3; ICAM-3; ICAM-R; CDW5; CD5 |
|---|---|
| Product description: | ICAMs are members of the immunoglobulin superfamily that is characterised by the presence of immunoglobulin-like domains. ICAM-3 is the major ligand for LFA-1 (CD11a/CD18) in the resting state. ICAM-3 may play a key role in initiating immune responses. ICAM 3.1 and ICAM 3.2 can be used to examine LFA-1/ICAM-3 adhesion. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Molecular weight: | 130 kDa |
| Immunogen: | ICAM-3Fc chimeric fusion protein. |
| Immunogen Uniprot ID: | P26006 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | ICAMs are members of the immunoglobulin superfamily that is characterised by the presence of immunoglobulin-like domains. ICAM-3 is the major ligand for LFA-1 (CD11a/CD18) in the resting state. ICAM-3 may play a key role in initiating immune responses. ICAM 3.1 and ICAM 3.2 can be used to examine LFA-1/ICAM-3 adhesion. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
DC-SIGN binds ICAM-3 isolated from peripheral human leukocytes through Lewis x residues. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. Analysis of the binding site on intercellular adhesion molecule 3 for the leukocyte integrin lymphocyte function-associated antigen 1. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.